The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.
 
Sarina Anne Piha-Paul
No Relationships to Disclose
 
Cinta Hierro
No Relationships to Disclose
 
Jens Oliver Funk
Employment - Principa Biopharma
Leadership - Principa Biopharma
Stock and Other Ownership Interests - Principa Biopharma
 
Steven Gourlay
Employment - Principa Biopharma
Leadership - Principa Biopharma
Stock and Other Ownership Interests - Principa Biopharma
Research Funding - Principa Biopharma
Patents, Royalties, Other Intellectual Property - Principa Biopharma
 
Patrick Smith
Employment - D3 Oncology Solutions; Principa Biopharma
Stock and Other Ownership Interests - Principa Biopharma
 
Eleni Venetsanakos
Employment - Novartis; Principa Biopharma
Stock and Other Ownership Interests - Principa Biopharma
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Genentech; Inflection Biosciences; Novartis; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; CytomX Therapeutics; Debiopharm Group; Genentech; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck; Merck Serono; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical